These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37288853)

  • 1. Risk Assessment Tool Implementation in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension.
    Yaylalı YT; Yağmur B; Sinan ÜY; Meriç M; Başarıcı İ; Kılıçkıran Avcı B; Şenol H; Nalbantgil S; Küçükoğlu S; Öngen Z
    Anatol J Cardiol; 2023 Aug; 27(8):479-485. PubMed ID: 37288853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension.
    Benza RL; Kanwar MK; Raina A; Scott JV; Zhao CL; Selej M; Elliott CG; Farber HW
    Chest; 2021 Jan; 159(1):337-346. PubMed ID: 32882243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Consistent Effectiveness and Safety of Macitentan Therapies Across Idiopathic and Congenital Heart Disease-Associated PulmonaryArterial Hypertension: A Single-Center Experience.
    Kaymaz C; Tanyeri S; Tokgöz HC; Akbal ÖY; Karagöz A; Keskin B; Kültürsay B; Hakgör A; Külahçıoğlu Ş; Bayram Z; Efe SÇ; Tanboğa İH; Doğan C; Akbulut M; Özdemir N
    Anatol J Cardiol; 2022 Oct; 26(10):778-787. PubMed ID: 36196862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 5. Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study.
    Deng X; Jin B; Li S; Li Y; Zhou H; Wu Y; Yan M; Hu Y; Qiu Q; Zhang G; Zheng X
    Clin Respir J; 2019 Nov; 13(11):693-699. PubMed ID: 31419027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study.
    Sitbon O; Chin KM; Channick RN; Benza RL; Di Scala L; Gaine S; Ghofrani HA; Lang IM; McLaughlin VV; Preiss R; Rubin LJ; Simonneau G; Tapson VF; Galiè N; Hoeper MM
    J Heart Lung Transplant; 2020 Apr; 39(4):300-309. PubMed ID: 32061506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Congenital heart disease with pulmonary artery hypertension in an Asian cohort-initial report from TACHYON (TAiwan congenital heart disease associated with pulmonarY arterial hypertension) registry.
    Chiu SN; Weng KP; Lin MC; Wang JN; Hwang BT; Dai ZK; Lin SM; Chang JS; Lin IC; Wu MH; Lu CW; Lin MT; Chen CA; Hua YC; Wu JM; Wang JK;
    Int J Cardiol; 2020 Oct; 317():49-55. PubMed ID: 32522677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).
    Benza RL; Miller DP; Gomberg-Maitland M; Frantz RP; Foreman AJ; Coffey CS; Frost A; Barst RJ; Badesch DB; Elliott CG; Liou TG; McGoon MD
    Circulation; 2010 Jul; 122(2):164-72. PubMed ID: 20585012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey.
    Yaylalı YT; Başarıcı I; Kılıçkıran Avcı B; Meriç M; Sinan ÜY; Şenol H; Küçükoğlu MS; Öngen Z
    Anatol J Cardiol; 2019 Jun; 21(6):322-330. PubMed ID: 31142721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis.
    Benza RL; Miller DP; Foreman AJ; Frost AE; Badesch DB; Benton WW; McGoon MD
    J Heart Lung Transplant; 2015 Mar; 34(3):356-61. PubMed ID: 25447572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripartum outcomes in a large population of women with pulmonary arterial hypertension associated with congenital heart disease.
    Li Q; Dimopoulos K; Liu T; Xu Z; Liu Q; Li Y; Zhang J; Gu H
    Eur J Prev Cardiol; 2019 Jul; 26(10):1067-1076. PubMed ID: 30971116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics, treatments and survival of pulmonary arterial hypertension associated with congenital heart disease in China: Insights from a national multicenter prospective registry.
    Xie F; Quan R; Zhang G; Tian H; Chen Y; Yu Z; Zhang C; Liu Y; Zhu X; Wu W; Zhu X; Yang Z; Gu Q; Xiong C; Han H; Cheng Y; He J; Wu Y
    J Heart Lung Transplant; 2023 Jul; 42(7):974-984. PubMed ID: 37002152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry.
    Frantz RP; Farber HW; Badesch DB; Elliott CG; Frost AE; McGoon MD; Zhao C; Mink DR; Selej M; Benza RL
    Chest; 2018 Jul; 154(1):126-135. PubMed ID: 29355551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry).
    Barst RJ; Ivy DD; Foreman AJ; McGoon MD; Rosenzweig EB
    Am J Cardiol; 2014 Jan; 113(1):147-55. PubMed ID: 24176071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry.
    Boucly A; Weatherald J; Savale L; de Groote P; Cottin V; Prévot G; Chaouat A; Picard F; Horeau-Langlard D; Bourdin A; Jutant EM; Beurnier A; Jevnikar M; Jaïs X; Simonneau G; Montani D; Sitbon O; Humbert M
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34737227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison Between REVEAL Lite 2 and COMPERA 2.0 for Risk Stratification in Pulmonary Arterial Hypertension.
    Sahay S; Villasmil Hernandez N; Wang F; Wooten M; Nguyen DT; Fauvel C; Benza R; Graviss EA
    Chest; 2024 Aug; 166(2):373-387. PubMed ID: 38447640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
    Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
    Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
    Mullin CJ; Khair RM; Damico RL; Kolb TM; Hummers LK; Hassoun PM; Steen VD; Mathai SC;
    Arthritis Rheumatol; 2019 Oct; 71(10):1691-1700. PubMed ID: 31066998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines.
    Dardi F; Manes A; Guarino D; Zuffa E; De Lorenzis A; Magnani I; Rotunno M; Ballerini A; Lo Russo GV; Nardi E; Galiè N; Palazzini M
    Open Heart; 2021 Oct; 8(2):. PubMed ID: 34667092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Derivation of a Risk Score (REVEAL-ECHO) Based on Echocardiographic Parameters of Patients With Pulmonary Arterial Hypertension.
    El-Kersh K; Zhao C; Elliott G; Farber HW; Gomberg-Maitland M; Selej M; Garcia-Ferrer J; Benza R
    Chest; 2023 May; 163(5):1232-1244. PubMed ID: 36634897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.